News
Company
Company

Select Year

An Interview with CEO Dr. Joan Shen: Starting a CNS Venture in an Economic Downturn

2024.05.28

An Interview with CEO Dr. Joan Shen: Starting a CNS Venture in an Economic Downturn

NeuShen Therapeutics Initiates First-in-Human Trial of NS-136, a Novel Selective M4 Receptor Positive Allosteric Modulator for the Treatment of Schizophrenia

2024.04.30

NeuShen Therapeutics Initiates First-in-Human Trial of NS-136, a Novel Selective M4 Receptor Positive Allosteric Modulator for the Treatment of Schizophrenia

NeuShen Therapeutics Announces Four Presentations at the 27th ASGCT Annual Meeting

2024.04.18

NeuShen Therapeutics Announces Four Presentations at the 27th ASGCT Annual Meeting

NeuShen Therapeutics Granted NMPA-CDE IND Approval for Highly Selective KCNQ2/3 Activator

2024.03.11

NeuShen Therapeutics Granted NMPA-CDE IND Approval for Highly Selective KCNQ2/3 Activator

< 1 >